What is Leuprolide?
Leuprolide is a GnRH agonist used to control sex-hormone signaling in several conditions. It belongs to a different pathway from growth-hormone secretagogues.
Biological role or research focus
GnRH-related control of reproductive hormones.
The clinical effect depends on sustained treatment and the condition; it should not be grouped with growth-hormone releasers.
Role reference: MedlinePlus · Leuprolide ↗
Names you may encounter
Lupron
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- GnRH agonist
- Main research area
- Reproductive-hormone suppression
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Leuprolide ↗
Quick answers
- Is Leuprolide FDA approved?
- Yes. Lupron Depot (e.g., NDA 019732), Eligard, Fensolvi and Camcevi for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty (indication varies by product). Source ↗
- Is Leuprolide safe?
- Approved GnRH agonist used for prostate cancer and other hormone conditions; it causes an early hormone surge and hot flashes and may raise heart, diabetes and bone-loss risks. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Leuprolide banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.1 Testosterone-stimulating peptides in males). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Historical prostate-cancer comparison (1984) | Human randomized trial | 199 patients with previously untreated metastatic prostate cancer. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 1984
Historical prostate-cancer comparison
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
- Population / model
- 199 patients with previously untreated metastatic prostate cancer.
- Study design
- Leuprolide versus diethylstilbestrol, with crossover permitted on progression or intolerable effects.
- Main finding
- Hormonal suppression and overall response were similar; adverse-effect patterns differed. One-year survival was not significantly different.
- Limits & context
- This is historical evidence against an older comparator, not a ranking of today’s treatment options. Prostate-cancer findings do not establish benefit for every other leuprolide indication.
Source: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
40 registered studies name Leuprolide as an intervention among the 100 most recently updated of 520 search results; 30 are recruiting or under way, 1 has not started recruiting yet, 8 completed and 1 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 40 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. ↗
The New England journal of medicine · 2023 Oct 19 · Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. ↗
The New England journal of medicine · 2020 Jun 4 · Clinical Trial, Phase III, Comparative Study, Equivalence Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Leuprolide. ↗
· 2026 Jan · Study Guide
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. ↗
The New England journal of medicine · 2026 Feb 5 · Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, Comparative Study
Risks & interactions
Approved GnRH agonist used for prostate cancer and other hormone conditions; it causes an early hormone surge and hot flashes and may raise heart, diabetes and bone-loss risks.
This entry follows the Vabrinty label for advanced prostate cancer; other leuprolide products are approved for other uses and groups and have their own labels. Evidence comes from clinical trials and postmarketing reports for GnRH agonists.
Take extra care with: Heart or blood pressure problemsDiabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeeding
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- People allergic to GnRH, GnRH agonist drugs or any product component
Interactions
- Drugs that prolong the QT interval: added heart rhythm risk with androgen deprivation
- Drugs linked to seizures, such as bupropion and SSRIs: seizures have been reported during leuprolide treatment
Serious risks
- Tumor flare early in treatment: bone pain, urinary blockage or spinal cord compression
- High blood sugar and new diabetes
- Heart attack, sudden cardiac death and stroke reported in men
- QT prolongation and seizures
- Severe skin reactions such as Stevens-Johnson syndrome
- Fetal harm in pregnancy; rare pituitary apoplexy
Common side effects
- hot flashes and sweating
- fatigue
- malaise
- testicular shrinkage
- decreased bone density
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Vabrinty (leuprolide) prescribing information ↗
Key precautions
Bone-density loss, hot flashes, mood changes, and metabolic or cardiovascular concerns can matter. Pregnancy is incompatible with these treatment uses; specific contraindications and monitoring belong to the product label.
Source: MedlinePlus · Leuprolide ↗
Regulatory status
- U.S. FDA approval
- Approved
Lupron Depot (e.g., NDA 019732), Eligard, Fensolvi and Camcevi for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty (indication varies by product). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.1 Testosterone-stimulating peptides in males
Named explicitly as a GnRH agonist analogue ("leuprorelin"); prohibited in males. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
Product-dependent uses include prostate cancer, central precocious puberty, endometriosis, and fibroid-associated anemia. Evidence for one indication should not be substituted for another.
Source: MedlinePlus · Leuprolide ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Mechanism & research rationale
Sustained GnRH-pathway stimulation ultimately suppresses gonadal hormone production. The resulting clinical effect depends on the treatment duration and the condition.
Source: MedlinePlus · Leuprolide ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- The clinical effect depends on sustained treatment and the condition; it should not be grouped with growth-hormone releasers.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is leuprolide intended to boost testosterone?
Sustained therapeutic use generally aims at suppression of reproductive hormones. It should not be grouped with testosterone-enhancement products.
Source: MedlinePlus · Leuprolide ↗
Why include an older cancer study?
It documents the clinical evidence history, while its older comparator limits relevance to today’s treatment choices.
Source: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
